Investigating GLP-1 RAs reveals their impact on women's health, addressing metabolic disorders, reproductive health, and ...

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with a rapidly increasing global prevalence. It is primarily characterized by insulin resistance, β-cell dysfunction, and impaired ...

I nvestigators analyzing the potential cognitive effects of antidiabetic medications in records of more than 1.5 million patients with type 2 diabetes mellitus (T2DM) found risks of dementia and ...

GLP-1 RA use linked to lower risks for myelodysplastic syndromes, myeloproliferative neoplasms compared with metformin. (HealthDay News) — For patients with type 2 diabetes (T2D), glucagon-like ...

Appropriate use of anti-diabetic medications with proven benefit in reducing CV events in people with T2DM with established CVD or in those at high risk for CVD shall further reduce the burden of ...

Glenmark Pharmaceuticals has launched Empagliflozin, a widely recognized SGLT2 inhibitor, in India. The drug has been introduced under the brand name Glempa (Empagliflozin 10/25 mg), along with its ...